Published in Eur J Clin Pharmacol on August 27, 2008
Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS (2010) 1.27
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother (2010) 1.19
Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One (2011) 1.11
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother (2012) 0.95
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. J Antimicrob Chemother (2010) 0.89
Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. Antimicrob Agents Chemother (2011) 0.88
Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol (2013) 0.83
Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. Br J Clin Pharmacol (2012) 0.80
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin Drug Metab Toxicol (2010) 0.79
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams. Pharmaceutics (2011) 0.76
Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. J Antimicrob Chemother (2016) 0.75
Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach. Eur J Clin Pharmacol (2016) 0.75
The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med (2003) 24.99
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed (1999) 8.87
HIV-TB co-infection: epidemiology, diagnosis & management. Indian J Med Res (2005) 3.05
Stability and performance of a population pharmacokinetic model. J Clin Pharmacol (1997) 2.71
Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos (1999) 2.18
Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet (2004) 1.82
Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos (1999) 1.73
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther (2001) 1.64
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother (1993) 1.62
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS (2000) 1.56
Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol (2001) 1.53
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother (2007) 1.45
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis (2006) 1.44
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet (2003) 1.43
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr (2001) 1.32
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother (1999) 1.32
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther (2005) 1.28
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol (2002) 1.23
Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos (1999) 1.16
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab (2004) 1.15
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release (1999) 1.14
The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients. HIV Med (2006) 1.11
Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis (2006) 1.10
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther (2005) 1.09
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis (2006) 1.09
Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit (2004) 1.05
Chronopharmacokinetics: implications for drug treatment. J Pharm Pharmacol (1999) 1.03
Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr (2006) 1.01
Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther (2004) 1.01
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol (2006) 0.99
No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol (2004) 0.95
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis (1997) 0.89
Body composition and nutritional parameters in HIV and AIDS patients. Clin Chem Lab Med (2002) 0.89
In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci (1998) 0.88
Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS (1999) 0.82
An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma. J Pharm Biomed Anal (2003) 0.82
Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. AAPS PharmSci (2000) 0.82
Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos (2006) 0.77
Role of drug metabolism for breaking tolerance and the localization of drug hypersensitivity. Toxicology (2005) 0.75
Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ (2008) 4.54
Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain. BMJ (2008) 4.14
A person based formula for allocating commissioning funds to general practices in England: development of a statistical model. BMJ (2011) 3.46
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev (2009) 2.77
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA (2008) 2.45
Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther (2006) 2.33
Antiretroviral therapy in a community clinic--early lessons from a pilot project. S Afr Med J (2003) 2.32
Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis (2013) 2.29
Global tuberculosis drug development pipeline: the need and the reality. Lancet (2010) 2.26
The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med (2005) 2.06
Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr (2011) 1.98
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother (2008) 1.95
Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother (2012) 1.88
Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrob Agents Chemother (2011) 1.68
Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther (2009) 1.66
Ankle strength and functional limitations in children and adolescents with type I osteogenesis imperfecta. Pediatr Phys Ther (2010) 1.56
Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis (2010) 1.54
The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother (2011) 1.49
Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. Br J Clin Pharmacol (2012) 1.48
Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol (2006) 1.45
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother (2007) 1.45
Repeated Time-to-event Analysis of Consecutive Analgesic Events in Postoperative Pain. Anesthesiology (2015) 1.43
The importance of early complementary feeding in the development of oral tolerance: concerns and controversies. Pediatr Allergy Immunol (2008) 1.42
Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med (2006) 1.42
Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol (2008) 1.39
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem (2014) 1.36
Crystal structure and functional analysis of tetracenomycin ARO/CYC: implications for cyclization specificity of aromatic polyketides. Proc Natl Acad Sci U S A (2008) 1.34
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J Med Chem (2013) 1.33
Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother (2012) 1.33
Analysis of the validity of the vignette approach to correct for heterogeneity in reporting health system responsiveness. Eur J Health Econ (2010) 1.32
Analysis of postural control synergies during quiet standing in healthy children and children with cerebral palsy. Clin Biomech (Bristol, Avon) (2002) 1.30
Formation of ovarian follicles during fetal development in sheep. Biol Reprod (2002) 1.27
Age-related differences in work injuries: a multivariate, population-based study. Am J Ind Med (2005) 1.26
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol (2011) 1.21
Paediatric use of second-line anti-tuberculosis agents: a review. Tuberculosis (Edinb) (2011) 1.19
Provision of antiretroviral therapy in South Africa: the nuts and bolts. Antivir Ther (2014) 1.17
Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One (2013) 1.16
Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J Virol Methods (2006) 1.15
Growth differentiation factor 9 and bone morphogenetic protein 15 are essential for ovarian follicular development in sheep. Biol Reprod (2002) 1.15
Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med (2009) 1.14
The effect of financial incentives on gatekeeping doctors: evidence from a natural experiment. J Health Econ (2005) 1.11
Antimuscarinic antibodies in Sjögren's syndrome: where are we, and where are we going? Arthritis Rheum (2005) 1.10
A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob Agents Chemother (2012) 1.10
Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis (2013) 1.09
Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis (2014) 1.07
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther (2003) 1.07
Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis (2010) 1.07
A Randomized Controlled Trial of Real-Time Electronic Adherence Monitoring With Text Message Dosing Reminders in People Starting First-Line Antiretroviral Therapy. J Acquir Immune Defic Syndr (2015) 1.05
Qualitatively distinct patterns of cytokines are released by human dendritic cells in response to different pathogens. Immunology (2005) 1.04
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol (2007) 1.04
Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties. J Virol (2005) 1.04
Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther (2009) 1.03
Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis (2009) 1.03
Stages of embryonic development in the Atlantic cod Gadus morhua. J Morphol (2004) 1.02
Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol (2006) 1.01
Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC Med (2013) 1.01
An ecological study of regional variation in work injuries among young workers. BMC Public Health (2007) 1.01
Antiparasitic compounds from Cornus florida L. with activities against Plasmodium falciparum and Leishmania tarentolae. J Ethnopharmacol (2012) 1.00
Measurement properties of the QuickDASH (disabilities of the arm, shoulder and hand) outcome measure and cross-cultural adaptations of the QuickDASH: a systematic review. Qual Life Res (2013) 0.99
Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine. Antimicrob Agents Chemother (2012) 0.99
In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos (2006) 0.99
The recovery patterns of back pain among workers with compensated occupational back injuries. Occup Environ Med (2007) 0.98
Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother (2010) 0.97
SOS regulatory elements are essential for UPEC pathogenesis. Microbes Infect (2010) 0.97
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob Agents Chemother (2012) 0.97
An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol (2007) 0.97
First Atmospheric Science Results from the Mars Exploration Rovers Mini-TES. Science (2004) 0.97
Evaluation of clinical threshold policies for cataract surgery among English commissioners. J Health Serv Res Policy (2012) 0.97
A cohort study of the recovery of health and wellbeing following colorectal cancer (CREW study): protocol paper. BMC Health Serv Res (2012) 0.97
Crystal structure and biochemical studies of the trans-acting polyketide enoyl reductase LovC from lovastatin biosynthesis. Proc Natl Acad Sci U S A (2012) 0.96
An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J Clin Pharmacol (2007) 0.96
Crystalloid deposits in the kidney. Nephrology (Carlton) (2005) 0.96
Expression of miRNAs in ovine fetal gonads: potential role in gonadal differentiation. Reprod Biol Endocrinol (2011) 0.95
Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother (2011) 0.95
Risk factors for 1-year mortality after postoperative mediastinitis. J Thorac Cardiovasc Surg (2006) 0.95
Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum. Malar J (2013) 0.95
Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology (2008) 0.94
Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS (2013) 0.94
Acceptability of the human papillomavirus vaccine among urban adolescent males. Am J Mens Health (2012) 0.94
The market for elective surgery: joint estimation of supply and demand. J Health Econ (2006) 0.93
Is patient choice an effective mechanism to reduce waiting times? Appl Health Econ Health Policy (2004) 0.92
Mitral valve repair versus replacement for isolated non-ischemic mitral regurgitation in patients with preoperative left ventricular dysfunction. A long-term follow-up echocardiography study. Eur J Echocardiogr (2005) 0.92
Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retroviruses (2009) 0.92
Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. J Pharm Sci (2005) 0.91